@article {Fleischmann-Struzek2021.02.25.21252347, author = {Carolin Fleischmann-Struzek and Norman Rose and Antje Freytag and Melissa Spoden and Hallie C. Prescott and Anna Schettler and Lisa Wedekind and Bianka Ditscheid and Josephine Storch and Sebastian Born and Peter Schlattmann and Christian G{\"u}nster and Konrad Reinhart and Christiane S. Hartog}, title = {Epidemiology and costs of post-sepsis morbidity, nursing care dependency, and mortality in Germany}, elocation-id = {2021.02.25.21252347}, year = {2021}, doi = {10.1101/2021.02.25.21252347}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Purpose To quantify the frequency and co-occurrence of new diagnoses consistent with post-sepsis morbidity, mortality, new nursing care dependency, and total healthcare costs after sepsis.Methods Population-based cohort study using healthcare claims data from 23 million beneficiaries of a German health insurance provider. We included adult patients with incident hospital-treated sepsis identified by ICD-10 codes in 2013-2014. New medical, psychological and cognitive diagnoses associated with post-sepsis morbidity; mortality; dependency on nursing care; and total health care costs in survivors were assessed to 3 years after hospital discharge.Results Among 116,507 sepsis patients who survived hospitalization for sepsis, 74.3\% had a new medical, psychological or cognitive diagnosis in the first year after discharge. 20.6\% and 3.8\% had new diagnoses in two and three domains, respectively. 31.5\% were newly dependent on nursing care, and 30.7\% died within the first year. In the second and third year, 65.8\% and 59.4\% of survivors had new diagnoses, respectively. Healthcare costs totaled an average 36,585 Euro/patient in three years, including index hospitalization costs. Occurrence of new diagnoses in predefined subgroups was: 73.7\% (survivors of non-severe sepsis), 75.6\% (severe sepsis), 78.3\% (ICU-treated sepsis), 72.8\% (non-ICU treated sepsis) and 68.5\% (survivors without prior diagnoses).Conclusions New medical, psychological and cognitive diagnoses consistent with post-sepsis morbidity are common after sepsis, including among patients with less severe sepsis, no prior diagnoses, and younger age. This calls for more efforts to elucidate the underlying mechanisms, define optimal screening for common new diagnoses, and test interventions to prevent and treat post-sepsis morbidity.Trial Registration DRKS00016340Take home message This large population-based cohort of over 100,000 survivors of hospital-treated sepsis found high rates and a broad spectrum of new diagnoses consistent with post-sepsis morbidity, frequent new nursing care dependency, and high long-term mortality 1-3 years post sepsis. Post-sepsis morbidity was not limited to the oldest survivors or those with the most severe illness, but also affected younger survivors and those without pre-existing diagnoses.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00016340Funding StatementGerman Innovations Fund of the Federal Joint Committee in Germany (G-BA) (grant number: 01VSF17010). The funder did not influence the design of the study, data collection, analysis and interpretation, as well as the writing of the manuscript. This manuscript does not represent the views of the Department of Veterans Affairs or the US government. This material is the result of work supported with resources and use of facilities at the Ann Arbor VA Medical Center Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Jena University Hospital institutional review board (2019-1282-Daten).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data utilized in this study cannot be made available in the manuscript, the supplemental files, or in a public repository due to German data protection laws (Bundesdatenschutzgesetz, BDSG). Therefore, they are stored on a secure drive in the AOK Research Institute (WIdO), to facilitate replication of the results. Generally, access to data of statutory health insurance funds for research purposes is possible only under the conditions defined in German Social Law (SGB V Paragraph 287). Requests for data access can be sent as a formal proposal specifying the recipient and purpose of the data transfer to the appropriate data protection agency. Access to the data used in this study can only be provided to external parties under the conditions of the cooperation contract of this research project and after written approval by the sickness fund. For assistance in obtaining access to the data, please contact wido{at}wido.bv.aok.de.}, URL = {https://www.medrxiv.org/content/early/2021/03/01/2021.02.25.21252347}, eprint = {https://www.medrxiv.org/content/early/2021/03/01/2021.02.25.21252347.full.pdf}, journal = {medRxiv} }